{"title":"一线奥西替尼治疗egfr突变的鳞状细胞肺癌1例报告","authors":"Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Eiji Tacheuchi","doi":"10.1002/cnr2.70273","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Epidermal growth factor receptor (<i>EGFR</i>) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for <i>EGF</i>R-mutated squamous cell lung carcinoma. We herein present a case of <i>EGFR</i>-mutated squamous cell lung carcinoma that responded to osimertinib.</p>\n </section>\n \n <section>\n \n <h3> Case</h3>\n \n <p>A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A mass was observed in the left lower lobe on chest CT. Squamous cell lung carcinoma, cT4N1M1b (adrenal metastasis) stage IVA, was diagnosed based on the findings of a CT-guided percutaneous lung biopsy and a CT scan revealing right adrenal metastasis. The primary tumor was subjected to a genomic analysis with the AmoyDx Pan Lung Cancer PCR panel, which revealed an <i>EGFR</i> mutation (exon 21 L858R). The PD-L1 tumor proportion score was 95%. Osimertinib was initiated as first-line targeted therapy. Tumor shrinkage was observed and maintained over 9 months of treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>We encountered a rare <i>EGFR</i>-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with <i>EGFR</i>-mutated squamous cell lung carcinoma.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 7","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70273","citationCount":"0","resultStr":"{\"title\":\"First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report\",\"authors\":\"Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Eiji Tacheuchi\",\"doi\":\"10.1002/cnr2.70273\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Epidermal growth factor receptor (<i>EGFR</i>) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for <i>EGF</i>R-mutated squamous cell lung carcinoma. We herein present a case of <i>EGFR</i>-mutated squamous cell lung carcinoma that responded to osimertinib.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case</h3>\\n \\n <p>A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A mass was observed in the left lower lobe on chest CT. Squamous cell lung carcinoma, cT4N1M1b (adrenal metastasis) stage IVA, was diagnosed based on the findings of a CT-guided percutaneous lung biopsy and a CT scan revealing right adrenal metastasis. The primary tumor was subjected to a genomic analysis with the AmoyDx Pan Lung Cancer PCR panel, which revealed an <i>EGFR</i> mutation (exon 21 L858R). The PD-L1 tumor proportion score was 95%. Osimertinib was initiated as first-line targeted therapy. Tumor shrinkage was observed and maintained over 9 months of treatment.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>We encountered a rare <i>EGFR</i>-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with <i>EGFR</i>-mutated squamous cell lung carcinoma.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9440,\"journal\":{\"name\":\"Cancer reports\",\"volume\":\"8 7\",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70273\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70273\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70273","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景表皮生长因子受体（EGFR）突变在鳞状细胞肺癌中是罕见的。egfr -酪氨酸激酶抑制剂通常对egfr突变的鳞状细胞肺癌效果较差。我们在此提出一例egfr突变的鳞状细胞肺癌对奥西替尼有反应。病例一名75岁妇女因痰血和左背部疼痛被转介到NHO高知医院。胸部CT示左下叶肿块。鳞状细胞肺癌，cT4N1M1b（肾上腺转移）IVA期，基于CT引导下经皮肺活检和CT扫描显示右侧肾上腺转移的结果诊断。原发肿瘤采用AmoyDx Pan Lung Cancer PCR面板进行基因组分析，发现EGFR突变（外显子21 L858R）。PD-L1肿瘤比例评分为95%。奥西替尼开始作为一线靶向治疗。观察到肿瘤缩小并维持治疗超过9个月。结论：我们遇到了一种罕见的egfr突变的鳞状细胞肺癌，对奥西替尼反应良好。奥西替尼可能是治疗egfr突变的鳞状细胞肺癌患者的一种选择。
First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report
Background
Epidermal growth factor receptor (EGFR) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for EGFR-mutated squamous cell lung carcinoma. We herein present a case of EGFR-mutated squamous cell lung carcinoma that responded to osimertinib.
Case
A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A mass was observed in the left lower lobe on chest CT. Squamous cell lung carcinoma, cT4N1M1b (adrenal metastasis) stage IVA, was diagnosed based on the findings of a CT-guided percutaneous lung biopsy and a CT scan revealing right adrenal metastasis. The primary tumor was subjected to a genomic analysis with the AmoyDx Pan Lung Cancer PCR panel, which revealed an EGFR mutation (exon 21 L858R). The PD-L1 tumor proportion score was 95%. Osimertinib was initiated as first-line targeted therapy. Tumor shrinkage was observed and maintained over 9 months of treatment.
Conclusion
We encountered a rare EGFR-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with EGFR-mutated squamous cell lung carcinoma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
